ClinicalTrials.gg
RecruitingNCT07762742Updated Nov 19, 2026

A Comparative Study of Percutaneous Pulsed Field Ablation Guided by Ultrasound Alone Versus Fluoroscopy in Patients With Atrial Fibrillation

An interventional study of Percutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation. and Patients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance. in Paroxysmal Atrial Fibrillation (PAF), sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 19, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 26 studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases — 19 open to participants now, 19 under way, none of them phase 3. Atrial Fibrillation · China National Center for Cardiovascular Diseases.

Planned enrollment
11th of 20
276 · median 283
Started
2026
with 5 others
No phase
16 of 26
11 open now
Primary completion
2029-02
later than 17 of 18 live
Registered
24th of 26
by date

Among the 26 studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases, this one is the 11th largest by planned enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2026, is one of 16 with no phase, reaches primary completion later than 17 of the 18 other live ones, and was the 24th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 963 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

19 of the 26 studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases are open now, in 2 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 609 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Atrial Fibrillation by China National Center for Cardiovascular Diseases, or all of them as a file.
02

Study summary

This prospective, randomized, multicenter, open-label, non-inferiority interventional study aims to compare the therapeutic efficacy of percutaneous pulsed field ablation (PFA) guided by ultrasound alone versus fluoroscopy in patients with paroxysmal atrial fibrillation (AF). The success rate of complete electrical isolation of pulmonary veins during the procedure was compared to verify that ultrasound-only guidance is non-inferior to fluoroscopic guidance.

03

Conditions studied

  • Paroxysmal Atrial Fibrillation (PAF)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18 to 75 years (including 18 years and 75 years of age).
  • Patients diagnosed with paroxysmal atrial fibrillation via 12-lead electrocardiography or ambulatory electrocardiography and scheduled to undergo pulsed field ablation.
  • Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the , and are willing to complete the follow-up according to the requirements of the program.

Exclusion criteria

Exclusion Criteria:

  • Atrial fibrillation secondary to electrolyte imbalance, thyroid disorders, or reversible non-cardiac causes;
  • Previous history of catheter ablation or cardiac surgery for atrial fibrillation;
  • Prior surgical history including patent foramen ovale closure, atrial septal defect closure or repair;
  • Implantation of left atrial appendage occluder, mechanical mitral valve prosthesis, or valvuloplasty ring containing metallic materials;
  • Concomitant other tachyarrhythmias requiring catheter ablation (e.g., atrioventricular reentrant tachycardia, atrioventricular nodal reentrant tachycardia, atrial tachycardia, atrial flutter, Wolff-Parkinson-White syndrome, etc.);
  • Persistent atrial fibrillation;
  • Left atrial anteroposterior diameter (LAD) > 55 mm on transthoracic echocardiography;
  • Women who are pregnant, breastfeeding, or of childbearing age with plans to become pregnant during the clinical trial;
  • Current participation in another pharmaceutical or medical device clinical study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
276 participants (estimated)

Study arms

  • Experimental
    Percutaneous pulsed field ablation performed under ultrasound-only guidance.

    Percutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation.

    Procedure: Percutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation.

  • Active comparator
    Pulsed field ablation performed under fluoroscopic guidance

    Patients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance.

    Procedure: Patients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance.

Interventions

  • ProcedurePercutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation.

    Percutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation.

  • ProcedurePatients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance.

    Patients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance.

06

What researchers measure

Primary outcomes

  1. Success rate of complete electrical isolation of pulmonary veins during the procedure

    The proportion of all pulmonary veins maintaining bidirectional block across ablation lines at 20 minutes after ablation completion.

    Time frame: Immediately post-procedure

Secondary outcomes

  1. The incidence of complications within 30 days after the procedure

    Observe the proportion of complications occurring within 30 days after the procedure. Such complications include pericardial effusion or cardiac tamponade requiring drainage, phrenic nerve palsy lasting more than 24 hours, severe vascular complications requiring intervention, stroke/transient ischemic attack, atrioesophageal fistula, and death.

    Time frame: Within 30 days post-procedure

  2. Success rate of atrial fibrillation ablation at 12 months post-procedure.

    Defined as the absence of AF, atrial flutter (AFL), or atrial tachycardia (AT) episodes ≥30 seconds on dynamic electrocardiogram (ECG) monitoring after the blanking period (90 days post-catheter ablation)

    Time frame: 12 months post-procedure

  3. The proportion of patients admitted to hospital or emergency departments due to atrial fibrillation recurrence within 12 months after the procedure.

    The proportion of patients admitted to hospital or emergency departments due to atrial fibrillation recurrence within 12 months after the procedure.

    Time frame: 12 months post-procedure

  4. The proportion of patients who received electrical cardioversion due to atrial fibrillation recurrence within 12 months after the procedure

    The proportion of patients who received electrical cardioversion due to atrial fibrillation recurrence within 12 months after the procedure.

    Time frame: 12 months post-procedure

  5. The proportion of patients undergoing repeat ablation surgery owing to atrial fibrillation within 12 months after the procedure

    The proportion of patients undergoing repeat ablation surgery owing to atrial fibrillation within 12 months after the procedure

    Time frame: 12 months post-procedure

  6. The proportion of patients who resumed antiarrhythmic drug therapy during follow-up after the blanking period

    The proportion of patients who resumed antiarrhythmic drug therapy during follow-up after the blanking period

    Time frame: From the end of the blanking period (within 90 days after catheter ablation) to 12 months post-procedure

  7. Improvement in the total EQ-5D quality-of-life questionnaire score at 12 months post-procedure compared with baseline

    The degree of improvement in total EQ-5D scores at 12 months after ablation relative to baseline levels

    Time frame: 12 months post-procedure

  8. Statistical analysis was performed to evaluate differences in fluoroscopic exposure dose between the two groups.

    Statistical analysis was performed to evaluate differences in fluoroscopic exposure dose between the two groups.

    Time frame: Immediately post-procedure

  9. Compare the length of hospital stay and postprocedural ICU/CCU stay duration between the two groups.

    After hospital discharge, the length of hospital stay for this admission and the duration of postoperative observation in CCU/ICU were compared between the two groups of patients.

    Time frame: through study completion, an average of 1 year

  10. Compare the procedural time and DSA fluoroscopy time between the two groups.

    Statistical analyses were performed to compare procedural duration and DSA fluoroscopy duration across the two groups.

    Time frame: Immediately post-procedure

  11. Compare the differences in costs between the two groups, including medical equipment costs, personnel costs, and patient hospitalization expenses.

    Total hospitalization costs incurred during this admission were compared between the two groups after hospital discharge.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Feb 2029, 29 months after the start.

Of 794 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 29 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 13, 2026
StartActual
Sep 2, 2026was Aug 2026
Primary completionEst.
Feb 28, 2029
CompletionEst.
Feb 28, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
1 site added — first site in China
Show site
  • Fuwai Hospital,CAMS&PUMC · Beijing, China
Nov 19, 2026
Start date
Aug 15, 2026→Sep 2, 2026 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Fuwai Hospital,CAMS&PUMC · Beijing, China
    Start date Aug 15, 2026→Sep 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07762742
Collaborators
Hangzhou Dinova EP Technology Co., Ltd
Responsible party
Sponsor
First posted
Aug 13, 2026
Start date
Sep 2, 2026
Primary completion
Feb 28, 2029 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

MIN TANG, Doctor
Contact
doctordangmin@sina.com
86+ 13810665178

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion